SOURCE: StockCall


February 03, 2011 08:06 ET

Opinions on Gilead Sciences Inc. and GlaxoSmithKline plc -- A Look at R&D in the Health Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - February 3, 2011) - offers investors comprehensive research on the biotechnology industry and has completed analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and GlaxoSmithKline plc (NYSE: GSK). Register with us today at to have free access to these researches. 

Strengthened regulatory efforts from the Food and Drug Administration have forced some biotechnology and drug manufacturers to readjust their approaches to research and development. Register now at to have free access to our reports on the biotechnology industry. is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Gilead Sciences Inc. and GlaxoSmithKline plc; all investors need to do is register for a complimentary membership at

Drug manufacturers have upped their collaborative efforts with Universities and looked to acquisitions to get drugs to market while spending less on R&D. Partnerships with Universities give drug makers the first opportunity at new technology in exchange for funding development. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Both Biotech and drug manufacturers have felt greater pressure to get products and drugs to market faster to generate revenue in a weaker economic environment. While autonomous developments yield the greatest returns, they require time, a luxury few companies within the industry have at the moment. Regulatory delays like the FDA's recent decline of an HIV drug marketing application for Gilead Sciences Inc. can upset revenue projections and have only made it more important for companies to get the most out of R&D dollars. Investors looking for free research on Gilead Sciences Inc. are welcome to sign up at

Some companies are also delaying R&D on projects to ensure a greater likelihood of getting them through the costly approval process. GlaxoSmithKline announced the discontinuation of clinical trials of an insomnia drug this week to conduct further research. Investors looking for free research on GlaxoSmithKline plc are welcome to sign up at

Overall, a greater sense of urgency to get products to market is affecting companies' attitudes towards R&D. Companies getting the greatest return on R&D dollars or that are effectively using alternative means to get products to market could be best positioned for growth moving forward.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information